IONS

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 1998, for ISIS Pharmaceuticals, Inc. (Note: The filing header lists "ISIS Pharmaceuticals, Inc." while the request metadata references "IONIS Pharmaceuticals Inc," which is the company's later name). ISIS is a biopharmaceutical company focused on research, drug discovery, and development. The company is not yet profitable and relies on collaborative research agreements, grants, and interest income. A significant milestone occurred during this quarter: the U.S. FDA approved the company's first product, Vitravene (for CMV retinitis), and the first commercial shipment was delivered.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $20.9 million for the quarter (from $13.8 million in 1997) and $34.8 million for the nine-month period (from $25.9 million in 1997). This was driven by a $7.5 million milestone payment for FDA approval of Vitravene, $0.6 million in product revenue from the first commercial shipment, and $4.0 million from a new exclusive patent license to CpG ImmunoPharmaceuticals.
• Expense Increases: Research and development (R&D) expenses rose to $16.5 million for the quarter (from $13.4 million) due to advancing compounds into more expensive clinical stages. General and administrative expenses increased to $2.3 million (from $1.8 million) to support growth.
• Interest Expense: Interest expense surged to $3.0 million for the quarter (from $0.8 million) due to $40 million in private debt financings completed in late 1997 and mid-1998. However, a significant portion ($2.1 million for the quarter) was accrued and did not require immediate cash payment.
• Net Loss: Despite revenue growth, the net loss for the nine-month period widened to $26.3 million (from $20.2 million in 1997) due to higher R&D and interest costs.

Outlook, Risks, and Management Commentary

• Liquidity Position: Management believes existing cash, cash equivalents, and short-term investments ($73.0 million), combined with interest income and contract revenue, are sufficient to meet anticipated requirements for approximately two years.
• Debt Structure: The company has $40 million in private debt (25M in 1997, 15M in 1998) with 14% interest. Principal and interest payments are deferred for the first five years. The carrying amount of these notes was $39.6 million as of September 30, 1998.
• Future Losses: The company expects to continue operating at a loss for several more years as it supports drug discovery and development.
• Year 2000 Issues: The company is assessing Year 2000 computer risks. Management believes the risk of material disruption to its own systems is minimal due to recent equipment purchases, but risks remain regarding suppliers and partners. No formal contingency plan is finalized yet.
• Legal Proceedings: The company is not a party to any material legal proceedings.

Investor Verification Checklist

• Verify the sustainability of revenue streams, specifically the timing of future milestone payments under collaborative agreements.
• Confirm the burn rate and the accuracy of the "two-year" liquidity runway given the high R&D spend and deferred debt obligations.
• Review the terms of the $40 million private debt financing, specifically the impact of the 14% interest rate and the $78 million accrued principal balance due in 2002.
• Monitor the commercial uptake of Vitravene following its first shipment to CIBA Vision Corporation.
• Assess the status of the Year 2000 remediation plan for critical suppliers and partners.